Jefferies analyst Akash Tewari maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on February 3 and set a price target of ...

Eli Lilly has named Winselow Tucker as President and General Manager for India. Tucker will oversee operations, including the Lilly India commercial organization and the Lilly Capability Centre India.

Truist raised the firm’s price target on Eli Lilly (LLY) to $1,038 from $1,029 and keeps a Buy rating on the shares. The firm is updating its ...

The company disclosed preliminary results in mid January, but it left out important metrics such as earnings per share for the fourth quarter.

Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the ...

I think Eli Lilly and Company's stock correction may be ending as demand for key drugs Zepbound and Mounjaro remains strong, despite recent sales guidance cuts. The company's high valuation ...

Eli Lilly's sales growth is coming short of expectations, which is a problem considering its valuation. The company does have a vast lineup and a deep pipeline that go beyond diabetes and obesity.

Wall Street expects a year-over-year increase in earnings on higher revenues when Eli Lilly (LLY) reports results for the quarter ended December 2024. While this widely-known consensus outlook is ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50 ...

Eli Lilly has said it is seeking permission to build a new biopharmaceutical manufacturing facility in Ireland that will be used to produce active ingredients for its biologic medicines ...